NeuroPace Q2 revenue $12.6M (+65% YoY); initial implants up 100%; reaffirms FY guidance

NeuroPace Inc

2021-Q2 EPS reported -$1.93 revenue$23,847,000

Total revenue $12.6M (+65% YoY); initial implant revenue $9.2M (+100% YoY, +14% QoQ).
Net loss $8.5M vs $8.8M; cash $127.9M; long-term debt $49.4M.
Reaffirmed FY2021 guidance: total revenue ~$47M, initial implant ~$36M.
Received up to $9.3M NIH BRAIN grant to evaluate RNS System for Lennox-Gastaut Syndrome.
Plans to start enrolling adolescent epilepsy patients before year-end; IDE for primary generalized epilepsy in 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.